A Phase Ib/II study(ClinicalTrials.gov identifier: NCT03072043; Study Registration Dates: 2017–03-02) enrolled fifty-five TP53-mutant patients (40 myelodysplastic syndrome(MDS), 11 AML, and 4 MDS/myeloproliferative neoplasms(MPN)) to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine [150]. Here, TP53 is linked to myeloproliferative disorder.